Sulfa Drugs as Inhibitors of Carbonic Anhydrase: New Targets for the Old Drugs

被引:19
|
作者
al-Rashida, Mariya [1 ]
Hussain, Sajad [1 ]
Hamayoun, Mehwish [2 ]
Altaf, Aisha [2 ]
Iqbal, Jamshed [2 ]
机构
[1] Chartered Univ, Forman Christian Coll, Dept Chem, Lahore 54600, Pakistan
[2] COMSATS Inst Informat Technol, Ctr Adv Drug Res, Abbottabad 22060, Pakistan
关键词
INCORPORATING 1,3,5-TRIAZINE MOIETIES; ISOZYME-II; SULFONAMIDES; IX; DESIGN; DERIVATIVES; EXPRESSION; TRANSPORT;
D O I
10.1155/2014/162928
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Sulfa drugs are well-known antibacterial agents containing N-substituted sulfonamide group on para position of aniline ring (NH2 RSO2 NHR'). In this study 2,4-dichloro-1,3,5-triazine derivatives of sulfa drugs, sulfamerazine (1b), sulfaquinoxaline (2b), sulfadiazine (3b), sulfadimidine (4b), and sulfachloropyrazine (5b) (1a-5a) were synthesized and characterized. Their carbonic anhydrase inhibition activity was evaluated against bovine cytosolic carbonic anhydrase isozyme II (bCA II). For the sake of comparison the CA inhibition activity of the parent sulfa drugs (1b-5b) was also evaluated. A significant increase in CA inhibition activity of sulfa drugs was observed upon substitution with 2,4-dichloro-1,3,5-triazine moiety. Molecular docking studies were carried out to highlight binding site interactions. ADME properties were calculated to evaluate drug likeness of the compounds.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Multicomponent chemistry in the synthesis of carbonic anhydrase inhibitors
    Kalinin, Stanislav
    Supuran, Claudiu T.
    Krasavin, Mikhail
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2016, 31 : 185 - 199
  • [32] Structural optimization of new class of selective carbonic anhydrase inhibitors: QSAR approach
    Pothen, Blessy
    Singh, Vineet
    Kumar, Surendra
    Tiwari, Meena
    INDIAN JOURNAL OF CHEMISTRY SECTION B-ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, 2010, 49 (02): : 224 - 233
  • [33] New hydroxypyrimidinone-containing sulfonamides as carbonic anhydrase inhibitors also acting as MMP inhibitors
    Esteves, M. Alexandra
    Ortet, Osvaldo
    Capelo, Anabela
    Supuran, Claudiu T.
    Marques, Sergio M.
    Santos, M. Amelia
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (12) : 3623 - 3627
  • [34] Synthesis and Evaluation of Amide and Thiourea Derivatives as Carbonic Anhydrase (CA) Inhibitors
    Hussain, Zahid
    Mahmood, Abid
    Shah, Qasim
    Imran, Aqeel
    Mughal, Ehsan Ullah
    Khan, Wajiha
    Baig, Ayesha
    Iqbal, Jamshed
    Mumtaz, Amara
    ACS OMEGA, 2022, 7 (50): : 47251 - 47264
  • [35] Quantitative Structure - Activity Relationships Study of Carbonic Anhydrase Inhibitors Using Logistic Regression Model
    Sahebjamee, Hassan
    Yaghmaei, Parichehre
    Abdolmaleki, Parviz
    Foroumadi, Ali Reza
    IRANIAN JOURNAL OF CHEMISTRY & CHEMICAL ENGINEERING-INTERNATIONAL ENGLISH EDITION, 2013, 32 (02): : 19 - 29
  • [36] Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors
    Tuccinardi, Tiziano
    Bertini, Simone
    Granchi, Carlotta
    Ortore, Gabriella
    Macchia, Marco
    Minutolo, Filippo
    Martinelli, Adriano
    Supuran, Claudiu T.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (06) : 1511 - 1515
  • [37] Pharmacological Properties of Sulfonamide Derivatives, New Inhibitors of Carbonic Anhydrase
    A. L. Khokhlov
    A. A. Shetnev
    M. K. Korsakov
    V. N. Fedorov
    A. N. Tyushina
    N. N. Volkhin
    V. P. Vdovichenko
    Bulletin of Experimental Biology and Medicine, 2023, 175 : 205 - 209
  • [38] Aromatase Inhibitors as a Promising Direction for the Search for New Anticancer Drugs
    Janowska, Sara
    Holota, Serhii
    Lesyk, Roman
    Wujec, Monika
    MOLECULES, 2024, 29 (02):
  • [39] Isosteviol - A new scaffold for the synthesis of carbonic anhydrase II inhibitors
    Denner, Toni C.
    Heise, Niels V.
    Csuk, Rene
    RESULTS IN CHEMISTRY, 2024, 7
  • [40] Sulfa drugs as model cocrystal formers
    Caira, Mino R.
    MOLECULAR PHARMACEUTICS, 2007, 4 (03) : 310 - 316